

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
10949/0138	Glaxo Pharmaceuticals UK Limited	Zantac Effervescent Tablets 300 mg	Ranitidine Hydrochloride HSE 336.00 mg* * Equivalent to Ranitidine 300.00 mg	Prescription Only Medicine For the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents, also indicated for the treatment of post-operative ulcer, Oesophageal Reflux disease and Zollinger-Ellison syndrome. Other patients with chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but is not associated with the preceding conditions may benefit from ranitidine treatment, also indicated for the following conditions where reduction or gastric secretion and acid output is desirable: The prophylaxis of gastro-intestinal haemorrhage from stress ulceration in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour.	10th April, 1994
10949/0139	Glaxo Pharmaceuticals UK Limited	Zantac Effervescent Granules 150 mg	Ranitidine Hydrochloride HSE 168.00 mg* * Equivalent to Ranitidine 150.00 mg	Prescription Only Medicine For the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. Also indicated for the prevention of NSAID associated duodenal ulcers. Also indicated for the treatment of post-operative ulcer, Zollinger-Ellison syndrome and oesophageal reflux disease including the long term management of healed oesophagitis. Other patients with chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but is not associated with the preceding conditions may benefit from ranitidine treatment. For the following conditions where reduction of gastric secretion and acid output is desirable: the prophylaxis of gastro-intestinal haemorrhage from stress ulceration in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour.	10th April, 1994
10949/0140	Glaxo Pharmaceuticals UK Limited	Zantac Effervescent Granules 300 mg	Ranitidine Hydrochloride HSE 336.00 mg* * Equivalent to Ranitidine 300.00 mg	Prescription Only Medicine Same as in PL 10949/0138	10th April, 1994
11314/0019	Seton Products Limited	Dijex Suspension	Magnesium Hydroxide Paste HSE 279.5 mg (equivalent to Magnesium Hydroxide) 85.0 mg Aluminium Hydroxide Paste HSE 2.91 gm (equivalent to Aluminium Hydroxide Gel) 4.9 gm	General Sale List For the relief of symptoms associated with acid indigestion and dyspepsia.	18th April, 1994
11847/0004	E-Z-EM Limited	'E-Z-Paque' Powder	Barium Sulphate EP 96.3045% w/w	Pharmacy Medicine For use as a positive contrast medium for radiographic visualisation of the gastro-intestinal tract.	29th April, 1994
12406/0008	Link Pharmaceuticals Limited	Plesmet Syrup	Ferrous Sulphate Heptahydrate BP 2.488% w/v Glycine BP 1.814% w/v	Pharmacy Medicine Treatment and prophylaxis of iron deficiency anaemia.	27th April, 1994